ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
GLP-1 receptor agonists during chemotherapy and radiotherapy: a supportive care call for nutrition-centred monitoring in the era of widespread prescribing.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo outline supportive-care considerations for using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during chemotherapy and/or radiotherapy, focusing on nutrition, body composition, and treatment tolerance.
methodsThis Comment addresses the supportive-care implications of this situation and draws on evidence from obesity trials, cardiovascular outcomes trials, pharmacokinetic studies, and oncology literature on sarcopenia and treatment tolerance.
resultsGLP-1 RAs improve cardiometabolic risk and, in selected high-risk populations, reduce major adverse cardiovascular events. However, body-composition studies indicate that their weight loss is not exclusively adipose; approximately 20-30% may be lean mass. In oncology, low skeletal muscle mass has been associated with higher rates of severe toxicity, more dose modifications, and worse survival. Delayed gastric emptying may lower maximum concentration and delay time to maximum concentration of oral co-medications while usually preserving overall exposure in non-oncology settings.
conclusionAlthough GLP-1 RAs have preventive and cardiometabolic benefits, these do not exclude possible concerns during active cancer therapy. Systematic screening, dietetic support, resistance exercise, and body-composition monitoring should guide initiation or continuation decisions during active treatment.
Indexed as
Identifiers
42008149What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.